To sell a new drug, it may be time to get inVentiv. inVentiv Health provides commercial, clinical, communications, and patient assistance services for 550 customers in the life sciences, biotech, and pharmaceutical industries. Its Commercial segment provides outsourced sales and marketing services, market research, data collection and management, recruitment, and training. The Clinical segment provides clinical staffing, clinical research and statistical analysis, and executive placement. It has served such notable clients as Johnson and Johnson, Bristol-Myers Squibb, and Novartis Pharmaceuticals. In mid-2010 private equity firm Thomas H. Lee Partners (THL) bought inVentiv Health for $1.1 billion.
The company has a presence in 40 countries spanning China, Europe, Japan, Korea, and the US.
inVentiv's business infrastructure is organized into three primary segments: Clinical, Commercial, and Consulting. The Clinical Services unit consists of Smith Hanley, MedFocus, HHI Statistical Services and Synergos, while its Commercial segment includes Health Products Research and Total Data Solutions. inVentiv's Consulting segment contains such public relations and branding agencies as GSW Worldwide, Chandler Chicco Agency, and Addison Whitney.
Ever since going private, inVentiv has been making a major push to extend its service lines and geographic reach through a recent flurry of acquisitions. In 2012 it purchased the clinical research business of specialty staffing firm Kforce for $50 million. The acquisition bolstered its capabilities in the placement of clinical research staff and contingent contract staffing to biotechnology and pharmaceutical companies. It also in 2012 obtained Kazaam Interactive, an interactive agency providing marketing and advertising services to health care brands, in a move that bolstered its Commercial segment.
The previous year inVentiv obtained PharmaNet Development Group, a global provider of drug development services to the pharmaceutical, biotechnology, generic drug and medical device industries, for an undisclosed amount. The deal broadened inVentiv's global presence to 40 countries and substantially enhance its early- and late-stage clinical development capabilities. It also propelled the company's annual revenue to roughly $2 billion.
Also in 2011 it acquired Campbell Alliance, a management consulting firm with strategic planning expertise in the pharmaceutical and biotech sectors. inVentiv merged its own consulting and market research operations, inVentiv Advance Insights, into Campbell Alliance, which continues to operate independently. Shortly after, the company purchased Ingenix's clinical trial outsourcing businesses -- i3 (including i3 Research, i3 Statprobe, and i3 Pharma Resourcing) -- for about $300 million. – less